SAVA
Price
$2.19
Change
+$0.11 (+5.29%)
Updated
Jul 9 closing price
Capitalization
105.79M
20 days until earnings call
SPRO
Price
$2.98
Change
-$0.06 (-1.97%)
Updated
Jul 10, 02:04 PM (EDT)
Capitalization
169.97M
28 days until earnings call
Interact to see
Advertisement

SAVA vs SPRO

Header iconSAVA vs SPRO Comparison
Open Charts SAVA vs SPROBanner chart's image
Cassava Sciences
Price$2.19
Change+$0.11 (+5.29%)
Volume$1.14M
Capitalization105.79M
Spero Therapeutics
Price$2.98
Change-$0.06 (-1.97%)
Volume$175
Capitalization169.97M
SAVA vs SPRO Comparison Chart in %
Loading...
SAVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SPRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SAVA vs. SPRO commentary
Jul 10, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SAVA is a StrongBuy and SPRO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 10, 2025
Stock price -- (SAVA: $2.19 vs. SPRO: $3.04)
Brand notoriety: SAVA and SPRO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SAVA: 98% vs. SPRO: 29%
Market capitalization -- SAVA: $105.79M vs. SPRO: $169.97M
SAVA [@Biotechnology] is valued at $105.79M. SPRO’s [@Biotechnology] market capitalization is $169.97M. The market cap for tickers in the [@Biotechnology] industry ranges from $314.48B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SAVA’s FA Score shows that 1 FA rating(s) are green whileSPRO’s FA Score has 1 green FA rating(s).

  • SAVA’s FA Score: 1 green, 4 red.
  • SPRO’s FA Score: 1 green, 4 red.
According to our system of comparison, SPRO is a better buy in the long-term than SAVA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SAVA’s TA Score shows that 5 TA indicator(s) are bullish while SPRO’s TA Score has 4 bullish TA indicator(s).

  • SAVA’s TA Score: 5 bullish, 5 bearish.
  • SPRO’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, SAVA is a better buy in the short-term than SPRO.

Price Growth

SAVA (@Biotechnology) experienced а +8.96% price change this week, while SPRO (@Biotechnology) price change was +4.83% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.89%. For the same industry, the average monthly price growth was +16.25%, and the average quarterly price growth was +20.89%.

Reported Earning Dates

SAVA is expected to report earnings on Jul 30, 2025.

SPRO is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Biotechnology (+9.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SPRO($170M) has a higher market cap than SAVA($106M). SPRO YTD gains are higher at: 195.146 vs. SAVA (-7.203). SPRO has higher annual earnings (EBITDA): -73.06M vs. SAVA (-145.89M). SAVA has more cash in the bank: 117M vs. SPRO (48.9M). SAVA has less debt than SPRO: SAVA (0) vs SPRO (3.96M). SPRO has higher revenues than SAVA: SPRO (28.3M) vs SAVA (0).
SAVASPROSAVA / SPRO
Capitalization106M170M62%
EBITDA-145.89M-73.06M200%
Gain YTD-7.203195.146-4%
P/E RatioN/A10.75-
Revenue028.3M-
Total Cash117M48.9M239%
Total Debt03.96M-
FUNDAMENTALS RATINGS
SAVA vs SPRO: Fundamental Ratings
SAVA
SPRO
OUTLOOK RATING
1..100
920
VALUATION
overvalued / fair valued / undervalued
1..100
22
Undervalued
59
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
5834
P/E GROWTH RATING
1..100
1006
SEASONALITY SCORE
1..100
75n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SAVA's Valuation (22) in the Pharmaceuticals Other industry is somewhat better than the same rating for SPRO (59) in the Pharmaceuticals Major industry. This means that SAVA’s stock grew somewhat faster than SPRO’s over the last 12 months.

SAVA's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as SPRO (100) in the Pharmaceuticals Major industry. This means that SAVA’s stock grew similarly to SPRO’s over the last 12 months.

SAVA's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as SPRO (98) in the Pharmaceuticals Major industry. This means that SAVA’s stock grew similarly to SPRO’s over the last 12 months.

SPRO's Price Growth Rating (34) in the Pharmaceuticals Major industry is in the same range as SAVA (58) in the Pharmaceuticals Other industry. This means that SPRO’s stock grew similarly to SAVA’s over the last 12 months.

SPRO's P/E Growth Rating (6) in the Pharmaceuticals Major industry is significantly better than the same rating for SAVA (100) in the Pharmaceuticals Other industry. This means that SPRO’s stock grew significantly faster than SAVA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SAVASPRO
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
86%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
71%
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
71%
Declines
ODDS (%)
Bearish Trend 14 days ago
88%
Bearish Trend 17 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
SAVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SPRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IDRSF2.800.05
+1.82%
Idorsia AG
ALBKF3.60N/A
N/A
Alpha Services and Holdings SA
ASBFF27.88N/A
N/A
Associated British Foods plc
CBAF28.35N/A
N/A
Citba Financial Corp.
RGBP0.05N/A
-6.93%
Regen Biopharma, Inc.

SAVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, SAVA has been loosely correlated with CRSP. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if SAVA jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SAVA
1D Price
Change %
SAVA100%
+5.29%
CRSP - SAVA
35%
Loosely correlated
+9.60%
IBRX - SAVA
29%
Poorly correlated
+2.95%
LXRX - SAVA
26%
Poorly correlated
+16.74%
AMRN - SAVA
26%
Poorly correlated
+2.97%
VKTX - SAVA
26%
Poorly correlated
+0.70%
More